ES2896053T3 - Biogel - Google Patents
Biogel Download PDFInfo
- Publication number
- ES2896053T3 ES2896053T3 ES16155589T ES16155589T ES2896053T3 ES 2896053 T3 ES2896053 T3 ES 2896053T3 ES 16155589 T ES16155589 T ES 16155589T ES 16155589 T ES16155589 T ES 16155589T ES 2896053 T3 ES2896053 T3 ES 2896053T3
- Authority
- ES
- Spain
- Prior art keywords
- fibrinogen
- binding
- carrier
- biogel
- carriers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 385
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 385
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 385
- 230000027455 binding Effects 0.000 claims abstract description 233
- 239000000969 carrier Substances 0.000 claims abstract description 85
- 239000002243 precursor Substances 0.000 claims abstract description 80
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 26
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 75
- 108010073385 Fibrin Proteins 0.000 claims description 67
- 102000009123 Fibrin Human genes 0.000 claims description 67
- 229950003499 fibrin Drugs 0.000 claims description 65
- 108090000190 Thrombin Proteins 0.000 claims description 52
- 229960004072 thrombin Drugs 0.000 claims description 52
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- 239000000178 monomer Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 24
- 230000000740 bleeding effect Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 9
- 108010000196 Factor XIIIa Proteins 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920000249 biocompatible polymer Polymers 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 59
- 239000003106 tissue adhesive Substances 0.000 description 43
- 108091006905 Human Serum Albumin Proteins 0.000 description 37
- 102000008100 Human Serum Albumin Human genes 0.000 description 37
- 206010052428 Wound Diseases 0.000 description 29
- 208000027418 Wounds and injury Diseases 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 24
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 23
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 23
- 239000003114 blood coagulation factor Substances 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 239000000499 gel Substances 0.000 description 17
- VWJLJHZPMZGDDV-HOCDWTQPSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)C1=CN=CN1 VWJLJHZPMZGDDV-HOCDWTQPSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 108010073651 fibrinmonomer Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 108010071289 Factor XIII Proteins 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 229940012444 factor xiii Drugs 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 102000008607 Integrin beta3 Human genes 0.000 description 4
- 108010020950 Integrin beta3 Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229940106780 human fibrinogen Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000565 sealant Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 3
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 3
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003534 oscillatory effect Effects 0.000 description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- -1 Factor Vila Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical group NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-M 2-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-M 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101150055229 FTA gene Proteins 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 101800003778 Fibrinopeptide B Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001061896 Homo sapiens Ras GTPase-activating protein 4 Proteins 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102100029555 Ras GTPase-activating protein 4 Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010017446 glycyl-prolyl-arginyl-proline Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000007056 transamidation reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0623607.9A GB0623607D0 (en) | 2006-11-27 | 2006-11-27 | Tissue adhesive |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2896053T3 true ES2896053T3 (es) | 2022-02-23 |
| ES2896053T8 ES2896053T8 (es) | 2022-03-03 |
Family
ID=37636565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16155589T Active ES2896053T3 (es) | 2006-11-27 | 2007-11-27 | Biogel |
| ES07824729T Active ES2570760T3 (es) | 2006-11-27 | 2007-11-27 | Biogel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07824729T Active ES2570760T3 (es) | 2006-11-27 | 2007-11-27 | Biogel |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9339584B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2099505B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5801994B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN101687061B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2007327100B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2669738C (cg-RX-API-DMAC10.html) |
| DK (1) | DK2099505T3 (cg-RX-API-DMAC10.html) |
| ES (2) | ES2896053T3 (cg-RX-API-DMAC10.html) |
| GB (1) | GB0623607D0 (cg-RX-API-DMAC10.html) |
| IL (1) | IL198699A (cg-RX-API-DMAC10.html) |
| PL (1) | PL2099505T3 (cg-RX-API-DMAC10.html) |
| RU (1) | RU2503464C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2008065388A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2358761B1 (en) | 2008-12-15 | 2015-08-05 | Council of Scientific & Industrial Research | A transparent xyloglucan/chitosan gel and a process for the preparation thereof |
| MX344402B (es) * | 2010-06-01 | 2016-12-14 | Baxter Int Inc * | Proceso para elaborar composiciones hemostaticas secas y estables. |
| GB201101740D0 (en) * | 2011-02-01 | 2011-03-16 | Haemostatix Ltd | Therapeutic agents with improved fibrinogen binding |
| GB201201751D0 (en) * | 2012-02-01 | 2012-03-14 | Haemostatix Ltd | Haemostatic wound dressing |
| EP2928511B1 (en) * | 2012-12-07 | 2020-04-22 | Baxter International Inc. | Hemostatic foam |
| IL230151A0 (en) * | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing a polymerization inhibitor |
| GB201400292D0 (en) * | 2014-01-08 | 2014-02-26 | Haemostatix Ltd | Peptide dendrimers and agents |
| IL231792A0 (en) | 2014-03-27 | 2014-08-31 | Omrix Biopharmaceuticals Ltd | Device and method for the preparation and administration of one-component fibrin glue |
| EA028039B1 (ru) * | 2014-09-05 | 2017-09-29 | Частное Учреждение Лаборатория Биотехнологических Исследований "3Д Биопринтинг Солюшенс" | Устройство и способы печати биологических тканей и органов |
| IL235751A0 (en) * | 2014-11-18 | 2015-02-26 | Omrix Biopharmaceuticals Ltd | An addition to the spray dryer |
| GB201508024D0 (en) | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic compositions |
| GB201508014D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic device |
| IL242984A0 (en) | 2015-12-08 | 2016-02-29 | Omrix Biopharmaceuticals Ltd | Thrombin microcapsules, their preparation and how to use them |
| US10159720B2 (en) | 2015-12-08 | 2018-12-25 | Omrix Biopharmaceuticals Ltd | Thrombin microcapsules, preparation and uses thereof |
| CN107432955B (zh) * | 2016-09-14 | 2020-09-04 | 四川蓝光英诺生物科技股份有限公司 | 用于制备生物构建体的方法和试剂盒 |
| WO2018065789A1 (en) | 2016-10-06 | 2018-04-12 | Matoke Holdings Limited | Antimicrobial compositions |
| EP3522717B1 (en) | 2016-10-06 | 2024-01-24 | Matoke Holdings Limited | Antimicrobial compositions |
| EP3749774A1 (en) | 2018-04-23 | 2020-12-16 | Danisco US Inc. | Synthesis of glucan comprising beta-1,3 glycosidic linkages with phosphorylase enzymes |
| CN110448719B (zh) * | 2019-06-28 | 2020-05-22 | 浙江大学 | 一种促进凝血的丝素-多肽电纺膜及其制备方法 |
| US20230105440A1 (en) * | 2021-10-06 | 2023-04-06 | Medtronic, Inc. | Anti-thrombogenic coating |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT359653B (de) | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| ATE13810T1 (de) | 1981-06-25 | 1985-07-15 | Serapharm Gmbh & Co Kg | Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundabdeckung. |
| US5357042A (en) | 1984-04-23 | 1994-10-18 | The General Hospital Corporation | Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity |
| US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
| IL103252A (en) | 1991-09-30 | 1997-03-18 | Du Pont Merck Pharma | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US5635477A (en) | 1991-09-30 | 1997-06-03 | The Dupont Merck Pharmaceutical Company | Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA |
| RU2096415C1 (ru) * | 1991-09-30 | 1997-11-20 | Дзе Дюпон Мерк Фармасьютикал Компани | Циклические пептиды или их фармацевтически приемлемые соли, фармацевтическая композиция |
| EP0691987A1 (en) | 1993-03-29 | 1996-01-17 | The Du Pont Merck Pharmaceutical Company | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa |
| EP0759762A4 (en) | 1994-05-02 | 1999-09-01 | Squibb & Sons Inc | RECOMBINANT FIBRIN CHAINS, FIBRIN AND FIBRIN APPROVED |
| AU717906B2 (en) * | 1994-12-07 | 2000-04-06 | American National Red Cross, The | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| DE69529917T2 (de) | 1994-12-16 | 2003-12-11 | Elan Drug Delivery Ltd., Ruddington | Vernetzte mikropartikel und ihre verwendung als arzneiträger |
| EP0831793A4 (en) | 1995-06-06 | 2000-11-15 | Hemosphere Inc | PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE |
| JP4024302B2 (ja) | 1996-05-17 | 2007-12-19 | クアドラント、 ドラッグ、 デリバリー、 リミテッド | 微粒子および創傷治療におけるその用途 |
| AU718956B2 (en) | 1996-10-21 | 2000-05-04 | Quadrant Healthcare (Uk) Limited | Platelet substitutes and conjugation methods suitable for their preparation |
| GB9724143D0 (en) * | 1997-11-14 | 1998-01-14 | Andaris Ltd | Pharmaceutical conjugate |
| DE19849589C1 (de) * | 1998-10-27 | 2000-06-15 | Glatt Process Technology Gmbh | Fibrin-Gewebekleber-Formulierung und Verfahren zu dessen Herstellung |
| AU7362301A (en) * | 2000-06-22 | 2002-01-02 | Sam L Austin | Bioadhesive compositions and methods of preparation and use |
| PL206194B1 (pl) * | 2001-01-25 | 2010-07-30 | Nycomed Pharma Asnycomed Pharma As | Sposób wytwarzania zawiesiny cząstek fibrynogenu i trombiny, zawiesina zawierająca fibrynogen, trombinę i alkohol oraz sposób powlekania nośnika taką zawiesiną |
| KR20050044725A (ko) * | 2001-12-04 | 2005-05-12 | 크리스토퍼 제이 울버튼 | 저장-안정성 피브린 밀봉제 |
| ES2325358T3 (es) * | 2002-01-14 | 2009-09-02 | "VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK", AFGEKORT "V.I.T.O." | Procedimiento para producir productos metalicos y ceramicos. |
| WO2003086494A1 (en) * | 2002-04-05 | 2003-10-23 | Baxter International Inc. | Storage stable liquid sealer protein complex |
| CN100525829C (zh) | 2002-04-15 | 2009-08-12 | 美国国家红十字会 | 检测混合物中配体和靶标的方法 |
| WO2004045494A2 (en) | 2002-11-20 | 2004-06-03 | Bar-Ilan University | Biological glue based on thrombin-conjugated nanoparticles |
| CA2489996A1 (en) * | 2003-05-08 | 2004-11-18 | Kaneka Corporation | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment |
| EP1638491A4 (en) | 2003-06-16 | 2008-05-28 | Univ Loma Linda Med | ABLEABLE MULTIFUNCTIONAL HEMOSTASIS |
| US7129210B2 (en) * | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
| US7927626B2 (en) | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| GB0323378D0 (en) | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
| CN1544098A (zh) * | 2003-11-12 | 2004-11-10 | 邹金生 | 高效神经生长因子生物胶及其制备和使用方法 |
| WO2005076827A2 (en) * | 2004-02-04 | 2005-08-25 | Universita' Degli Studi Di Pavia | Fbsa compositions for use in promoting fibrinogen aggregation and potentiating fibrin polymerization |
| US7833978B2 (en) * | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
| US20060034935A1 (en) | 2004-07-22 | 2006-02-16 | Pronovost Allan D | Compositions and methods for treating excessive bleeding |
| ES2530989T3 (es) | 2004-10-20 | 2015-03-09 | Ethicon Inc | Hemostático absorbible |
| GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
-
2006
- 2006-11-27 GB GBGB0623607.9A patent/GB0623607D0/en not_active Ceased
-
2007
- 2007-11-27 EP EP07824729.3A patent/EP2099505B1/en active Active
- 2007-11-27 RU RU2009119257/15A patent/RU2503464C2/ru active
- 2007-11-27 US US12/515,721 patent/US9339584B2/en active Active
- 2007-11-27 EP EP16155589.1A patent/EP3095468B1/en active Active
- 2007-11-27 DK DK07824729.3T patent/DK2099505T3/en active
- 2007-11-27 CA CA2669738A patent/CA2669738C/en active Active
- 2007-11-27 ES ES16155589T patent/ES2896053T3/es active Active
- 2007-11-27 ES ES07824729T patent/ES2570760T3/es active Active
- 2007-11-27 CN CN200780044184XA patent/CN101687061B/zh active Active
- 2007-11-27 PL PL07824729T patent/PL2099505T3/pl unknown
- 2007-11-27 WO PCT/GB2007/004538 patent/WO2008065388A2/en not_active Ceased
- 2007-11-27 JP JP2009537703A patent/JP5801994B2/ja active Active
- 2007-11-27 AU AU2007327100A patent/AU2007327100B2/en active Active
-
2009
- 2009-05-12 IL IL198699A patent/IL198699A/en active IP Right Grant
-
2013
- 2013-06-20 JP JP2013130066A patent/JP2013188550A/ja active Pending
-
2016
- 2016-04-13 US US15/098,028 patent/US9913876B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009119257A (ru) | 2011-01-10 |
| PL2099505T3 (pl) | 2016-08-31 |
| CN101687061A (zh) | 2010-03-31 |
| EP2099505B1 (en) | 2016-02-17 |
| CA2669738C (en) | 2017-05-30 |
| EP3095468B1 (en) | 2021-08-11 |
| EP2099505A2 (en) | 2009-09-16 |
| JP2010510818A (ja) | 2010-04-08 |
| AU2007327100A1 (en) | 2008-06-05 |
| US20160287659A1 (en) | 2016-10-06 |
| EP3095468A1 (en) | 2016-11-23 |
| HK1231419A1 (en) | 2017-12-22 |
| JP5801994B2 (ja) | 2015-10-28 |
| GB0623607D0 (en) | 2007-01-03 |
| US9339584B2 (en) | 2016-05-17 |
| JP2013188550A (ja) | 2013-09-26 |
| US20100249044A1 (en) | 2010-09-30 |
| IL198699A (en) | 2014-12-31 |
| US9913876B2 (en) | 2018-03-13 |
| CN101687061B (zh) | 2013-03-27 |
| WO2008065388A2 (en) | 2008-06-05 |
| ES2570760T3 (es) | 2016-05-20 |
| DK2099505T3 (en) | 2016-05-30 |
| AU2007327100B2 (en) | 2014-03-06 |
| WO2008065388A3 (en) | 2009-11-26 |
| CA2669738A1 (en) | 2008-06-05 |
| IL198699A0 (en) | 2010-02-17 |
| ES2896053T8 (es) | 2022-03-03 |
| RU2503464C2 (ru) | 2014-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9913876B2 (en) | Biogel | |
| ES2879558T3 (es) | Apósito hemostático para heridas | |
| JP4954370B2 (ja) | 共役不飽和基に対する求核付加反応によって作製される生体適合材料 | |
| RU2635510C2 (ru) | Прокоагулянтные пептиды, их производные и их применение | |
| Sierra | Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications | |
| CA2295247C (en) | Compositions containing thrombin and microfibrillar collagen | |
| ES2551388T3 (es) | Modificación de agentes de entrecruzamiento enzimáticos para controlar las propiedades de las matrices entrecruzadas | |
| JP6717747B2 (ja) | フィブリノゲン結合ペプチドを含むペプチドデンドリマー | |
| ES2702657T3 (es) | Adhesivo de fibrina de un componente que comprende un inhibidor de la polimerización | |
| GB2488023B (en) | Therapeutic agents with improved fibrinogen binding | |
| US20090285753A1 (en) | Novel haptotactic peptides | |
| ES2968449T3 (es) | Composiciones hemostáticas | |
| HK1231419B (en) | Biogel |